Gheorghe Liana, Iacob Speranta, Csiki Irma Eva, Ghioca Mihaela, Iacob Razvan, Constantinescu Ileana, Chiper Bogdan, Huiban Laura, Muzica Cristina, Girleanu Irina, Tiuca Nicoleta, Diaconu Sorina, Sandulescu Daniela Larisa, Rogoveanu Ion, Suceveanu Andra Iulia, Furtunescu Florentina, Pop Corina, Trifan Anca
Fundeni Clinical Institute, 022328 Bucharest, Romania.
"Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Viruses. 2024 Dec 31;17(1):52. doi: 10.3390/v17010052.
Hepatitis B (HBV) and Delta (HDV) virus infections pose critical public health challenges, particularly in Romania, where HDV co-infection is underdiagnosed.
This study investigates the epidemiology, risk factors, and clinical outcomes of HBV/HDV co-infection in vulnerable populations, leveraging data from the LIVE(RO2) program. Conducted between July 2021 and November 2023, the program screened 320,000 individuals across 24 counties, targeting socially disadvantaged groups such as rural residents, the Roma community, and those lacking health insurance.
Among 6813 hepatitis B surface antigen (HBsAg)-positive individuals, HDV antibody prevalence was 4.87%, with active replication confirmed in 75.6% of HDV-positive cases. Regional disparities emerged, with higher HDV prevalence and replication rates in the Eastern region compared to the South. HDV-positive individuals were more likely to be younger, male, and from rural or socioeconomically disadvantaged backgrounds. Clinically, HDV co-infection correlated with increased liver stiffness, advanced fibrosis stages, and lower steatosis levels compared to HBV mono-infection. Psychiatric comorbidities were more prevalent among HDV-positive patients, highlighting the need for integrated care.
This study underscores the urgent need for targeted public health interventions, including enhanced screening, education, and access to novel antiviral therapies like bulevirtide to address the significant burden of HBV/HDV co-infection in Romania.
乙型肝炎(HBV)和丁型肝炎(HDV)病毒感染构成了严峻的公共卫生挑战,在罗马尼亚尤为如此,该国丁型肝炎病毒合并感染的诊断率较低。
本研究利用LIVE(RO2)项目的数据,调查了弱势群体中HBV/HDV合并感染的流行病学、危险因素和临床结局。该项目于2021年7月至2023年11月开展,对24个县的32万人进行了筛查,目标人群为农村居民、罗姆社区成员和无医疗保险等社会弱势群体。
在6813例乙型肝炎表面抗原(HBsAg)阳性个体中,HDV抗体患病率为4.87%,75.6%的HDV阳性病例证实有病毒活跃复制。出现了地区差异,东部地区的HDV患病率和复制率高于南部地区。HDV阳性个体更可能是年轻人、男性,且来自农村或社会经济弱势背景。临床上,与HBV单一感染相比,HDV合并感染与肝硬度增加、纤维化晚期和较低的脂肪变性水平相关。HDV阳性患者的精神疾病合并症更为普遍,这凸显了综合治疗的必要性。
本研究强调迫切需要有针对性的公共卫生干预措施,包括加强筛查、教育以及提供如布列韦肽等新型抗病毒疗法,以应对罗马尼亚HBV/HDV合并感染的重大负担。